Playback speed
10 seconds
What's New in Atopic Dermatitis and Itch Treatment?
By
Masterclasses in Dermatology
FEATURING
Gil Yosipovitch
By
Masterclasses in Dermatology
FEATURING
Gil Yosipovitch
519 views
March 6, 2024
Disclaimer: On September 13, 2024, the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), ...
read more ↘ a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
↖ read less
read more ↘ a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe atopic dermatitis (eczema) that is not well controlled despite treatment with topical prescription therapies.
↖ read less
Comments 2
Login to view comments.
Click here to Login
Recommended
AUTOPLAY